Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 150

1.

Error occurred: cannot get document summary

PMID:
27937617

2.

Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.

Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D.

J Pain Symptom Manage. 2009 Oct;38(4):522-32. doi: 10.1016/j.jpainsymman.2008.12.004.

PMID:
19608377
3.

AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program.

Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Chang S, Helfand M.

J Clin Epidemiol. 2010 May;63(5):513-23. doi: 10.1016/j.jclinepi.2009.03.009.

PMID:
19595577
4.

A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer.

Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman BJ.

Radiother Oncol. 2009 Feb;90(2):189-95. doi: 10.1016/j.radonc.2008.12.017.

PMID:
19167120
5.

Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.

Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):1-8. doi: 10.1016/j.ijrobp.2008.07.059.

PMID:
19111400
6.

Outcome in recurrent head neck cancer treated with salvage-IMRT.

Studer G, Graetz KW, Glanzmann C.

Radiat Oncol. 2008 Dec 17;3:43. doi: 10.1186/1748-717X-3-43.

7.

Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.

van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR.

Radiat Oncol. 2008 Dec 9;3:41. doi: 10.1186/1748-717X-3-41.

8.

Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?

Studer G, Seifert B, Glanzmann C.

Strahlenther Onkol. 2008 Nov;184(11):580-5. doi: 10.1007/s00066-008-1951-y.

PMID:
19016016
9.

Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer.

Anand AK, Chaudhoory AR, Shukla A, Negi PS, Sinha SN, Babu AA, Munjal RK, Dewan AK, Kumar K, Doval DC, Vaid AK.

Br J Radiol. 2008 Nov;81(971):865-71. doi: 10.1259/bjr/31334499.

PMID:
18941046
10.

First-year trends in self-reported general health predict survival in patients with head and neck cancer.

Jameson MJ, Karnell LH, Christensen AJ, Funk GF.

Arch Otolaryngol Head Neck Surg. 2008 Sep;134(9):958-64. doi: 10.1001/archotol.134.9.958.

PMID:
18794441
11.

Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5. doi: 10.1016/j.ijrobp.2008.04.048.

PMID:
18635320
12.

Clinical application of intensity-modulated radiotherapy for head and neck cancer.

Ballivy O, Galiana SantamarĂ­a R, Lozano Borbalas A, Guedea Edo F.

Clin Transl Oncol. 2008 Jul;10(7):407-14. Review.

PMID:
18628069
13.

Chemotherapy in the treatment of locally advanced head and neck cancer.

Forastiere AA.

J Surg Oncol. 2008 Jun 15;97(8):701-7. doi: 10.1002/jso.21012. Review.

PMID:
18493921
14.

Intensity-modulated radiation therapy.

Lee NY, Terezakis SA.

J Surg Oncol. 2008 Jun 15;97(8):691-6. doi: 10.1002/jso.21014. Review.

PMID:
18493919
15.

Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma.

Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):737-46. doi: 10.1016/j.ijrobp.2008.01.027.

PMID:
18486356
16.

Intensity-modulated radiotherapy for head-and-neck cancer in the community setting.

Seung S, Bae J, Solhjem M, Bader S, Gannett D, Hansen EK, Louie J, Underhill K, Cha C.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1075-81. doi: 10.1016/j.ijrobp.2008.02.016.

PMID:
18486355
17.

Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE.

J Clin Oncol. 2008 Jul 1;26(19):3138-46. doi: 10.1200/JCO.2007.12.7597.

18.

Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.

Dijkema T, Terhaard CH, Roesink JM, Braam PM, van Gils CH, Moerland MA, Raaijmakers CP.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1101-9. doi: 10.1016/j.ijrobp.2008.02.059.

PMID:
18472355
19.

Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.

Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8. doi: 10.1016/j.ijrobp.2008.02.048.

PMID:
18468812
20.

Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer.

Rosenthal DI, Chambers MS, Fuller CD, Rebueno NC, Garcia J, Kies MS, Morrison WH, Ang KK, Garden AS.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):747-55. doi: 10.1016/j.ijrobp.2008.01.012.

PMID:
18455324
Items per page

Supplemental Content

Support Center